Radiation Benefits Mixed After Breast-Preserving Surgery

Share this article:
Radiation Benefits Mixed After Breast-Preserving Surgery
Radiation Benefits Mixed After Breast-Preserving Surgery

THURSDAY, Jan. 26 (HealthDay News) -- Treatment with radiation therapy after excision of ductal carcinoma in situ (DCIS) in women age 60 is associated with a slight improvement in survival, but may increase the likelihood of eventual mastectomy, according to a study published in the Feb. 1 issue of Cancer.

Rinaa S. Punglia, M.D., M.P.H., of the Dana-Farber Cancer Institute/Brigham and Women's Hospital in Boston, and colleagues studied the influence of treatment outcomes using a Markov decision model designed to simulate the clinical course of DCIS for a woman aged 60 who has undergone excision, with and without the addition of radiation therapy. They examined the risk of local recurrence, the likelihood of invasive disease, surgery choices after recurrence, and patient age at diagnosis in relation to treatment outcomes.

Using sensitivity analyses, the researchers found that radiation therapy after DCIS for a woman aged 60 improved overall disease-free survival by 2.1 months, while decreasing the chances of keeping both breasts by 8.6 percent; the latter decrease was due to a higher likelihood of eventual invasive recurrence or new breast cancer diagnosis requiring mastectomy. With increasing age at diagnosis, the difference in outcomes between the treatment strategies became smaller.

"Radiation for DCIS is prophylactic; it reduces the risk of invasive recurrence, which is the only lethal form of breast cancer, while increasing the probability of eventual mastectomy," the authors write. "The absolute magnitude of both effects is modest, such that personal patient preferences should drive decision making."

Abstract
Full Text (subscription or payment may be required)

This article originally appeared here.
Share this article:
You must be a registered member of ONA to post a comment.
close

Next Article in Daily Oncology News

Sign Up for Free e-newsletters

April Contest: Win a Pebble Watch

Start the contest today

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Daily Oncology News

Statins may lower progression risk for renal cancer

Statins may lower progression risk for renal cancer

Use of statins is associated with a reduced risk of progression of localized renal cell carcinoma, according to research.

Cyramza approved by FDA for stomach cancer

Cyramza approved by FDA for stomach cancer

Cyramza (ramucirumab) has been approved by the U.S. Food and Drug Administration to treat cancer of the stomach.

Cancer patients require anxiety and depression screening

Cancer patients require anxiety and depression screening

It is important to recognize and treat anxiety or depression among cancer patients, according to a clinical guideline published in the Journal of Clinical Oncology.